- Home
- ORI vs QGEN Comparison
ORI vs QGEN Comparison
Compare ORI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORI | QGEN |
|---|---|---|
| Founded | 1923 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ORI | QGEN |
|---|---|---|
| Price | $43.13 | $45.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $49.00 | ★ $50.07 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 01-22-2026 | 02-04-2026 |
| Dividend Yield | 2.68% | ★ 3.34% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | ★ 3.32 | 1.84 |
| Revenue | ★ $8,748,900,000.00 | $2,070,781,000.00 |
| Revenue This Year | $10.22 | $7.07 |
| Revenue Next Year | $6.10 | $6.14 |
| P/E Ratio | ★ $13.05 | $24.57 |
| Revenue Growth | ★ 7.08 | 5.32 |
| 52 Week Low | $33.00 | $37.63 |
| 52 Week High | $46.76 | $51.88 |
Technical Indicators
Market Signals| Indicator | ORI | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 45.00 |
| Support Level | $45.35 | $45.13 |
| Resistance Level | $46.76 | $46.02 |
| Average True Range (ATR) | 0.62 | 0.62 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 14.01 | 40.96 |
Price Performance
Historical ComparisonAbout ORI Old Republic International Corporation
Old Republic International Corp offers a diverse range of specialized insurance products to individuals and institutions. The company operates in two segments: Specialty Insurance and Title Insurance. The Insurances provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).